NYSE:IQV IQVIA (IQV) Stock Price, News & Analysis $153.42 +2.32 (+1.54%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$158.24 +4.82 (+3.14%) As of 05/2/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About IQVIA Stock (NYSE:IQV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IQVIA alerts:Sign Up Key Stats Today's Range$152.41▼$156.3150-Day Range$141.38▼$191.6952-Week Range$135.97▼$252.88Volume1.70 million shsAverage Volume1.44 million shsMarket Capitalization$27.05 billionP/E Ratio20.46Dividend YieldN/APrice Target$237.62Consensus RatingModerate Buy Company OverviewIQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.Read More… IQVIA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks99th Percentile Overall ScoreIQV MarketRank™: IQVIA scored higher than 99% of companies evaluated by MarketBeat, and ranked 22nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageIQVIA has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IQVIA's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.55% Earnings GrowthEarnings for IQVIA are expected to grow by 12.55% in the coming year, from $10.84 to $12.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IQVIA is 20.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.99.Price to Earnings Ratio vs. SectorThe P/E ratio of IQVIA is 20.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.Price to Earnings Growth RatioIQVIA has a PEG Ratio of 1.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIQVIA has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IQVIA's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.68% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIQVIA does not currently pay a dividend.Dividend GrowthIQVIA does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.69 Percentage of Shares Shorted1.68% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.89 News SentimentIQVIA has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for IQVIA this week, compared to 17 articles on an average week.Search Interest7 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IQVIA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of IQVIA is held by insiders.Percentage Held by Institutions89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IQVIA's insider trading history. Receive IQV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter. Email Address IQV Stock News HeadlinesIQVIA (IQV) Projected to Post Quarterly Earnings on TuesdayMay 5 at 1:51 AM | americanbankingnews.comIQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?May 1, 2025 | msn.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 5, 2025 | Brownstone Research (Ad)Why New Wegovy Deals Won’t Restore Novo Nordisk’s Obesity LeadApril 30, 2025 | msn.comZydus Lifesciences receives final approval from USFDA for Niacin Extended-Release TabletsApril 30, 2025 | msn.comPollen count levels in CT will remain high this week amid warm weatherApril 29, 2025 | msn.comIQVIA Holdings Inc. (IQV): Among Billionaire Israel Englander’s Stock Picks with Huge Upside PotentialApril 28, 2025 | insidermonkey.comIQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association AwardsApril 28, 2025 | businesswire.comSee More Headlines IQV Stock Analysis - Frequently Asked Questions How have IQV shares performed this year? IQVIA's stock was trading at $196.51 on January 1st, 2025. Since then, IQV shares have decreased by 21.9% and is now trading at $153.42. View the best growth stocks for 2025 here. How were IQVIA's earnings last quarter? IQVIA Holdings Inc. (NYSE:IQV) announced its earnings results on Thursday, February, 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by $0.21. IQVIA had a trailing twelve-month return on equity of 28.81% and a net margin of 8.91%. Read the conference call transcript. Does IQVIA have any subsidiaries? IQVIA subsidiaries include these companies: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and others. Who are IQVIA's major shareholders? IQVIA's top institutional investors include Bank of New York Mellon Corp (0.59%), Sumitomo Mitsui Trust Group Inc. (0.59%), KBC Group NV (0.34%) and Envestnet Asset Management Inc. (0.27%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly and John G Danhakl. View institutional ownership trends. How do I buy shares of IQVIA? Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IQVIA own? Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK). Company Calendar Last Earnings2/06/2025Today5/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNYSE:IQV CIK1478242 Webwww.iqvia.com Phone(919) 998-2000FaxN/AEmployees86,000Year Founded2016Price Target and Rating Average Stock Price Target$237.62 High Stock Price Target$276.00 Low Stock Price Target$160.00 Potential Upside/Downside+54.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$7.50 Trailing P/E Ratio20.46 Forward P/E Ratio14.15 P/E Growth1.99Net Income$1.37 billion Net Margins8.91% Pretax Margin10.83% Return on Equity28.81% Return on Assets7.02% Debt Debt-to-Equity Ratio2.12 Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual Sales$15.41 billion Price / Sales1.76 Cash Flow$13.14 per share Price / Cash Flow11.68 Book Value$34.45 per share Price / Book4.45Miscellaneous Outstanding Shares176,315,000Free Float173,282,000Market Cap$27.05 billion OptionableOptionable Beta1.34 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:IQV) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.